March 12, 2025 Bio/Pharma/CRO Licensing, IP, and Legal M&A, Partnerships PAI Top-10

Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity

Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388 Collaboration will complement Roche’s portfolio in the field of cardiovascular, renal, and metabolic (CVRM) diseases Obesity is a heterogeneous disease with over 200 related comorbidities, including cardiovascular and metabolic diseases, and is... Read more

March 2, 2025 Bio/Pharma/CRO

Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies

First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies Basel, 2 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new... Read more

January 31, 2025 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PAI Top-10 PR/Corporate

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be eligible for a targeted treatment, which could significantly improve their outcomes. The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since... Read more

January 8, 2025 Atomic Spectroscopy Bio/Pharma/CRO Lab Top-10 Molecular Spectroscopy Product Launch

Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research

Groundbreaking LUMOS II ILIM QCL-based IR microscope sets new standards in speed and resolution BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the launch of the LUMOS™ II ILIM , a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to... Read more

December 19, 2024 Bio/Pharma/CRO

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints Prasinezumab continues to be well tolerated and no new safety signals were observed Roche is further evaluating the data and will work together with health authorities to determine next steps Basel, 19 December 2024 – Roche (SIX: RO,... Read more

November 26, 2024 Bio/Pharma/CRO

Roche reports update on Phase III SKYSCRAPER-01 study results

Basel, 26 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).  SKYSCRAPER-01 is a global phase III, randomised, double-blind study evaluating tiragolumab plus... Read more

October 31, 2024 Bio/Pharma/CRO PAI Top-10 Product Launch

New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

ItovebiTM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in the INAVO120 study1 The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR-positive, HER2-negative breast cancer with a PIK3CA mutation, one... Read more

October 2, 2024 Bio/Pharma/CRO Lab Top-10 Microscopy

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business MUNICH–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Dynamic Biosensors GmbH , a pioneering company known for its breakthroughs in biosensor development,... Read more

July 2, 2024 Bio/Pharma/CRO Lab Top-10 Life Science Tools Molecular Spectroscopy

Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin

The Avance® 1.2 GHz NMR system will enable advanced studies of biomolecular structures and function in structural biology, pharmacology, and cellular biology BERLIN–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second... Read more

April 8, 2024 Acad, Gov/Utilities Atomic Spectroscopy Bio/Pharma/CRO Environ, Ag./Food & Bev Lab Top-10 Molecular Spectroscopy

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies ASILOMAR, Calif.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as... Read more